Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

BMC Gastroenterology
Phunchai CharatcharoenwitthayaTHASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C

Abstract

We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6. We analyzed data from 1021 patients with HCV infection (506 with genotype 1; 16 with genotype 2; 314 with genotype 3; 13 with genotype 4; 166 with genotype 6) who received 12 to 24 weeks of daclatasvir plus sofosbuvir (n = 767), ledipasvir/sofosbuvir (n = 197), or sofosbuvir/velpatasvir (n = 57), with or without ribavirin in 12 centers across Thailand to estimate sustained virologic response at post-treatment week 12 (SVR12). Overall, SVR12 rate was 98.0% (95% confidence interval [CI], 96.7-98.8%) with daclatasvir plus sofosbuvir, 97.9% (95% CI, 94.8-99.2%) with ledipasvir/sofosbuvir, and 96.5% (95% CI, 88.1-99.0%) with sofosbuvir/velpatasvir. SVR12 was achieved by 99.2% (95% CI, 97.9-99.7%) of subjects with genotype 1 infection, 100% (95% CI, 78.5-100%) of those with genotype 2 infection, 96.7% (95% CI, 94.0-98.2%) of those with genotype 3 infection, 90.9% (95% CI, 62.3-98.4%) of those with genotype 4 infection, and 96.7% (95% CI 92.5-98.6%) of those with genotype 6 infection. Patients with advanced liver disease were at risk...Continue Reading

References

May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Mar 15, 2011·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Lisa I BackusLarry A Mole
Jun 18, 2011·Liver International : Official Journal of the International Association for the Study of the Liver·William SievertFrancesco Negro
Dec 27, 2012·JAMA : the Journal of the American Medical Association·Adriaan J van der MeerHarry L A Janssen
Jan 17, 2014·The New England Journal of Medicine·Mark S SulkowskiUNKNOWN AI444040 Study Group
Apr 12, 2014·The New England Journal of Medicine·Kris V KowdleyUNKNOWN ION-3 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-2 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-1 Investigators
Jan 24, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David R NelsonUNKNOWN ALLY-3 Study Team
May 20, 2015·Gastroenterology·Michael CharltonUNKNOWN SOLAR-1 Investigators
Nov 17, 2015·The New England Journal of Medicine·Michael P CurryUNKNOWN ASTRAL-4 Investigators
Nov 17, 2015·The New England Journal of Medicine·Jordan J FeldUNKNOWN ASTRAL-1 Investigators
Nov 18, 2015·The New England Journal of Medicine·Graham R FosterUNKNOWN ASTRAL-3 Investigators
Jan 30, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Vincent LeroyAlexander J Thompson
Apr 27, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Lisa I BackusLarry A Mole
May 24, 2016·Journal of Hepatology·Luca Saverio BelliUNKNOWN European Liver and Intestine Association (ELITA)
Jul 13, 2016·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Raoel MaanJordan J Feld
Dec 3, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jagpreet ChhatwalRaymond T Chung
Dec 13, 2016·Liver International : Official Journal of the International Association for the Study of the Liver·Tao LiLei Wang
Feb 9, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Carlos Fernández CarrilloJosé Luis Calleja
Feb 13, 2017·Journal of Hepatology·Jose Luis CallejaUNKNOWN Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group
Apr 14, 2017·The Lancet. Gastroenterology & Hepatology·UNKNOWN Polaris Observatory HCV Collaborators
May 16, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Varun SaxenaK Rajender Reddy
Aug 27, 2017·Journal of Hepatology·Juan Manuel PascasioMaría-Carlota Londoño
Nov 1, 2017·The American Journal of Gastroenterology·Mindie H NguyenLinda Henry
Feb 7, 2018·Journal of Viral Hepatitis·P A CortesiUNKNOWN European Liver and Intestine Transplant Association (ELITA)
Apr 14, 2018·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Oct 15, 2018·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Chun-Ming HongChun-Jen Liu
Aug 30, 2019·Hepatology International·Chung-Feng HuangUNKNOWN REAL-C Investigators

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
surgical resection

Software Mentioned

SPSS
mITT

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.